Chubb Ltd

CB is consolidating within a broader uptrend, with medium- and long-term biases bullish but short-term momentum remains weak. Given oversold context and attractive valuation, patient accumulation on dips toward the $335 support zone and 200-day SMA aligns with strategy. Entries should be deferred until price shows acceptance around established support levels.

• ↑Q2 operating earnings $2.8B ($7.26/shr), +14.6% YoY; combined ratio 83.8
• ↑Tangible book value rose 17.1% YoY to $195.45/share
• ↓Casualty pricing fails to keep pace with rising loss costs